Patents Assigned to Vanderbilt University
  • Patent number: 11364278
    Abstract: The present invention relates to compositions and methods for treating autoimmune, microbial, metabolic, neoplastic, and posttraumatic diseases mediated by inflammation in a subject. Compositions and methods including at least one importin beta-selective nuclear transport modifier (NTM) and/or at least one importin alpha-selective NTM, and/or at least one importin alpha-specific NTM, and/or at least one inhibitor of importin alpha and importin beta complex formation may be administered to a subject to modulate the transport of transcription factors, mediated by nuclear import adaptors, into the nucleus of a cell resulting in a decrease or abrogation of inflammation.
    Type: Grant
    Filed: February 24, 2020
    Date of Patent: June 21, 2022
    Assignee: VANDERBILT UNIVERSITY
    Inventors: Jack J. Hawiger, Jozef Zienkiewicz
  • Publication number: 20220183617
    Abstract: A method of measuring a biomechanical parameter of soft biological tissue is described. The method includes a pre-measurement process wherein an impulse applying device applies a pre-pressure to a surface of the tissue via an end portion contacting the tissue surface. While maintaining the pre-pressure, the device generates at least two impulses separated by a time interval, each impulse causing the end portion to impart to the tissue an action with certain parameters, each action inducing a response of the tissue. A value of a biomechanical parameter of the tissue is determined from each response induced. A determination is made as to whether the determined values of the biomechanical parameter are sufficiently similar to each other to indicate that the pre-pressure, the parameters of the end portion actions and the time interval are acceptable for use in a measurement process to be conducted on the surface of the tissue.
    Type: Application
    Filed: March 23, 2020
    Publication date: June 16, 2022
    Applicants: VANDERBILT UNIVERSITY, UNIVERSITY OF TARTU
    Inventors: Arved Vain, Eric Tkaczyk, Mihkel Pöldemaa
  • Patent number: 11357829
    Abstract: This disclosure provides methods for treatment comprising co-administering insulin and glucagon to a subject, and co-formulations comprising insulin and glucagon.
    Type: Grant
    Filed: February 2, 2018
    Date of Patent: June 14, 2022
    Assignee: Vanderbilt University
    Inventors: Alan Cherrington, David Maggs, Soumitra Ghosh, Christopher A. Rhodes, Jui-Chen Lin
  • Patent number: 11352671
    Abstract: Provided herein are methods and compositions for determining the susceptibility of Parkinson's disease patients to optimized drug therapy (ODT) and or deep brain stimulation (DBS) therapy.
    Type: Grant
    Filed: May 2, 2016
    Date of Patent: June 7, 2022
    Assignees: VANDERBILT UNIVERSITY, BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY
    Inventors: David Charles, Mallory Hacker, Caryl E. Sortwell, Jack W. Lipton
  • Patent number: 11351135
    Abstract: A method for administration of citrulline for the treatment of sickle cell disease and other complications of sickle cell disease thereof.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: June 7, 2022
    Assignees: VANDERBILT UNIVERSITY, THE UNIVERSITY OF MISSISSIPPI MEDICAL CENTER
    Inventors: Marshall L. Summar, Frederick W. Barr, Suvankar Majumdar
  • Patent number: 11352344
    Abstract: Disclosed herein are substituted hexahydro-1H-cyclopenta[c]pyrrole compounds of formula (Ia), which may be useful as antagonists of the muscarinic acetylcholine receptor M4 (mAChR M4). Also disclosed herein are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating disorders using the compounds and compositions.
    Type: Grant
    Filed: October 31, 2018
    Date of Patent: June 7, 2022
    Assignee: Vanderbilt University
    Inventors: Craig W. Lindsley, P. Jeffrey Conn, Darren W. Engers, Kayla J. Temple
  • Patent number: 11345741
    Abstract: The present disclosure is directed to antibodies binding to and neutralizing the coronavirus designated SARS-CoV-2 and methods for use thereof.
    Type: Grant
    Filed: March 25, 2021
    Date of Patent: May 31, 2022
    Assignee: Vanderbilt University
    Inventors: James E. Crowe, Jr., Seth Zost, Robert Carnahan, Pavlo Gilchuk
  • Patent number: 11345743
    Abstract: The present disclosure is directed to antibodies binding to and neutralizing Chikungunya virus (CHIKV) and methods for use thereof.
    Type: Grant
    Filed: October 10, 2019
    Date of Patent: May 31, 2022
    Assignee: VANDERBILT UNIVERSITY
    Inventors: James E. Crowe, Jr., Scott A. Smith, Terence Dermody, Laurie Silva
  • Patent number: 11325896
    Abstract: Disclosed herein are substituted 2-azaspiro[3.3]heptane compounds of formula (I?), which may be useful as antagonists of the muscarinic acetylcholine receptor M4 (mAChR M4). Also disclosed herein are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating disorders using the compounds and compositions.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: May 10, 2022
    Assignee: Vanderbilt University
    Inventors: Craig W. Lindsley, P. Jeffrey Conn, Darren W. Engers, Aaron M. Bender, Logan A. Baker
  • Patent number: 11318028
    Abstract: Systems and methods for a running controller for a lower limb device including at least a powered knee joint are provided. The method includes collecting real-time sensor information for the lower limb device and configuring the lower limb device to a first state in a finite state model for an activity mode including the running mode. The method further includes, based on the sensor information, transitioning the lower limb device from a current state to a subsequent state in the finite state model for the detected mode when a pre-defined criteria for transitioning to the subsequent state is met, and repeating the transitioning until the activity mode changes. In the system and method, the finite state model includes at least one stance state and at least one swing state, where the at least one stance state includes at least one absorption state and at least one propulsion state.
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: May 3, 2022
    Assignee: Vanderbilt University
    Inventors: Michael Goldfarb, Amanda Shultz, Brian Lawson
  • Patent number: 11319304
    Abstract: Pyridine quinoline compounds which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds, for example, in treating neurological and psychiatric disorders or other disease states associated with glutamate dysfunction.
    Type: Grant
    Filed: June 28, 2018
    Date of Patent: May 3, 2022
    Assignee: Vanderbilt University
    Inventors: P. Jeffrey Conn, Craig W. Lindsley, Andrew S. Felts, Colleen M. Niswender, Rory A. Capstick, Paul K. Spearing, Sean R. Bollinger
  • Patent number: 11318137
    Abstract: The present invention relates to quinazoline compounds and compositions that modulate Ras signaling. Compounds and compositions of the present invention are useful in the treatment of cancers and other disease states associated with Ras dysfunction (e.g., Ras-associated autoimmune leukoproliferative disorder, or certain types of mitochondrial dysfunction) in a subject, for example a mammal or a human.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: May 3, 2022
    Assignee: Vanderbilt University
    Inventors: Alex G. Waterson, Jason R. Abbott, J. Phillip Kennedy, Stephen W. Fesik, Qi Sun, Jason Phan, Michael C. Burns, Pratiq Patel
  • Patent number: 11312986
    Abstract: Disclosed are methods of preparing everninomicin analogs by genetic alteration of Micromonospora carbonacea. Everninomicin analogs prepared by these methods and methods of using these analogs to treat infections are also disclose.
    Type: Grant
    Filed: June 26, 2020
    Date of Patent: April 26, 2022
    Assignee: VANDERBILT UNIVERSITY
    Inventors: Brian O. Bachmann, Emilianne M. Limbrick, Kasia Derewacz
  • Patent number: 11305039
    Abstract: The present invention relates generally to shape memory polymer devices that are porous. The porosity of the device may generate advantageous neovascularization, decrease inflammation, and decrease fibrosis. The device may include a surface having a pore size of 500-750 microns and a pore spacing of 220-250 microns.
    Type: Grant
    Filed: March 19, 2020
    Date of Patent: April 19, 2022
    Assignees: Vanderbilt University, Venostent, Inc.
    Inventor: Timothy C. Boire
  • Patent number: 11305018
    Abstract: Disclosed herein are glycidol-based polymers, nanoparticles, and methods related thereto useful for drug delivery. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: February 25, 2020
    Date of Patent: April 19, 2022
    Assignee: Vanderbilt University
    Inventors: Eva M. Harth, Dain B. Beezer, GuangZhao Li, Benjamin R. Spears, David M. Stevens
  • Patent number: 11299481
    Abstract: Disclosed herein are substituted hexahydro-1H-cyclopenta[c]pyrrole compounds, which may be useful as antagonists of the muscarinic acetylcholine receptor M4 (mAChR M4). Also disclosed herein are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating disorders using the compounds and compositions.
    Type: Grant
    Filed: October 20, 2018
    Date of Patent: April 12, 2022
    Assignee: Vanderbilt University
    Inventors: Craig W. Lindsley, P. Jeffrey Conn, Darren W. Engers, Julie L. Engers, Kayla J. Temple, Aaron M. Bender, Logan A. Baker
  • Patent number: 11299535
    Abstract: The present disclosure is directed to antibodies binding to Aspergillus allergens and methods for use thereof.
    Type: Grant
    Filed: October 15, 2019
    Date of Patent: April 12, 2022
    Assignee: VANDERBILT UNIVERSITY
    Inventor: Scott A. Smith
  • Patent number: 11293863
    Abstract: Provided are improved optical detection systems and methods for using same, which systems and methods comprise single channel interferometric detection systems and methods for determining a characteristic property of samples. Such interferometric detection systems and methods employ a light beam that impinges two or more discrete zones along a channel, thereby avoiding variations that can result in increases in detection limits and/or measurement errors.
    Type: Grant
    Filed: February 4, 2019
    Date of Patent: April 5, 2022
    Assignee: Vanderbilt University
    Inventors: Darryl J. Bornhop, Michael Kammer
  • Patent number: 11291382
    Abstract: Disclosed are catheter systems and methods of using the catheter system to acquire mucosal impedance data of a patient. Also disclosed are methods of classifying or otherwise identifying esophageal conditions in a subject based on mucosal impedance data acquired using a catheter system. Unlike conventions systems that require subjective input from a physician to render a diagnosis, the systems and methods described herein can utilize the mucosal impedance measurements to generate a probability that the subject's esophagus corresponds to an esophageal condition or a set of esophageal conditions. In one embodiment, a classification model is used to generate the probability. The classification model may generate the probability based at least in part on a change in the mucosal impedance measurements between a distal location and a proximal location on the subject's esophagus.
    Type: Grant
    Filed: June 3, 2019
    Date of Patent: April 5, 2022
    Assignees: Diversatek Healthcare, Inc., Vanderbilt University
    Inventors: Michael F. Vaezi, Charles Lindsay, James M. Prinster
  • Patent number: 11287427
    Abstract: In spite of significant efforts to identify ?-cell-specific markers for ?-cell imaging and purification, progress has been limited. Herein is disclosed a novel biomarker of human pancreatic ?-cells, CD39L3 (also known as ectonucleoside triphosphate diphosphohydrolase-3 (NTPDase3)). Disclosed are compositions and methods for purifying and imaging ?-cell using anti-CD39L3 antibodies.
    Type: Grant
    Filed: June 11, 2018
    Date of Patent: March 29, 2022
    Assignees: VANDERBILT UNIVERSITY, THE UNITED STATES AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
    Inventors: Alvin C. Powers, Marcela Brissova, Chunhua Dai, Neil Phillips, Diane Saunders